The safety of suprmaximal doses of candesartan cilexetil (160mg) in the reduction of proteinuria in chronic renal disease

被引：0
|
作者：
Weinberg, A
Haneiwich, R
Oza, N
Weinberg, M
机构：
[1] Roger Williams Med Ctr, Providence, RI USA
[2] Boston Univ, Med Ctr Affilil, Boston, MA 02215 USA
来源：
JOURNAL OF HYPERTENSION | 2003年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 8 条
  • [1] The safety and efficacy of supramaximal doses of candesartan cilexetil (160mg) in chronic renal disease patients naive to angiotensin receptor blockade therapy
    Weinberg, AJ
    Haneiwich, R
    Weinberg, MS
    AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 103A - 103A
  • [2] The safety of supramaximal doses,of candesartan cilexitil (160 mg) in hypertensive subjects with chronic, renal disease.
    Weinberg, MS
    Weinberg, AJ
    Zappe, D
    Haneiwich, R
    Ljunggren, A
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 763A - 763A
  • [3] Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction
    Omoto, K
    Tanabe, K
    Tokumoto, T
    Shimmura, H
    Ishida, H
    Toma, H
    TRANSPLANTATION, 2003, 76 (08) : 1170 - 1174
  • [4] Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease
    Homma, K
    Hayashi, K
    Kanda, T
    Yoshioka, K
    Takamatsu, I
    Tatematsu, S
    Kumagai, H
    Wakino, S
    Saruta, T
    JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (12) : 879 - 884
  • [5] Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease
    K Homma
    K Hayashi
    T Kanda
    K Yoshioka
    I Takamatsu
    S Tatematsu
    H Kumagai
    S Wakino
    T Saruta
    Journal of Human Hypertension, 2004, 18 : 879 - 884
  • [6] SAFETY AND USEFULNESS OF THE REDUCTION OF DOSES OF IMATINIB TO 300 MG IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (LMC) AND PROFOUND MOLECULAR RESPONSE SUSTAINED. EXPERIENCE OF OUR CENTRE
    Redondo Velao, S.
    Perez Sanchez, I
    Martinez Laperche, C.
    Buno, I
    Diez-Martin, J. L.
    Osorio Prendes, S.
    HAEMATOLOGICA, 2015, 100 : 194 - 194
  • [7] SAFETY AND EFFICACY OF EVEROLIMUS GIVEN AT 10 MG/DAY IN ADVANCED RENAL CELL CARCINOMA (RCC) PATIENTS WITH STAGE III TO V CHRONIC KIDNEY DISEASE (CKD)
    Cosmai, Laura
    Porta, Camillo
    Foramitti, Marina
    Masini, Cristina
    Sabbatini, Roberto
    Malberti, Fabio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 157 - 157
  • [8] ADMINISTRATION OF HIGH DOSES (> 1000 MG) OF IRON ISOMALTOSIDE IN CHRONIC KIDNEY DISEASE PATIENTS WITH IRON DEFICIENCY ANAEMIA GIVES AN EFFECTIVE INCREASE IN HAEMOGLOBIN WITHOUT ADDITIONAL SAFETY CONCERNS
    Bhandari, Sunil
    Wikstrom, Bjorn
    Kalra, Philip
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
1